Literature DB >> 8490186

A splice site mutation of alpha-spectrin gene causing skipping of exon 18 in hereditary elliptocytosis.

N Alloisio1, R Wilmotte, J Maréchal, P Texier, L Denoroy, C Féo, Z Benhadji-Zouaoui, J Delaunay.   

Abstract

Spectrin Oran (alpha II/21) has been reported previously as a variant of the alpha II domain. Its expression level is low (10% of total spectrin) in heterozygotes denoting a major disadvantage of the mutated alpha-chain dimer or tetramer with respect to their normal counterparts. Spectrin Oran is associated with symptomatic elliptocytosis in the homozygous state. A 1-minute digestion time allowed to perceive a fast trypsin cleavage (not existing normally) after Arg 890 (helix 3 of repeating segment alpha 9). The responsible change was the lack of amino acids 822 to 862 (helix 2 of repeating segment alpha 8). Such a situation fits with the phasing of spectrin according to which mutated helix 2 and distorted helix 3 are adjacent to one another. The internal position of the structural change accounts for the slight self-association defect. The ultimate genetic lesion was a G to A substitution (intronic position-1) in the acceptor splice site of intron 17 resulting in skipping of exon 18. The substitution also created an acceptor splice site 1 base downstream, but the latter was used at a low grade.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8490186

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  2 in total

1.  Combination of two mutant alpha spectrin alleles underlies a severe spherocytic hemolytic anemia.

Authors:  H Wichterle; M Hanspal; J Palek; P Jarolim
Journal:  J Clin Invest       Date:  1996-11-15       Impact factor: 14.808

2.  Spectrin Tunis (Sp alpha (I/78)) in a Korean family with hereditary elliptocytosis.

Authors:  Eunhee Han; Ahhyun Kim; Joonhong Park; Myungshin Kim; Yonggoo Kim; Kyungja Han; Yoo-Jin Kim
Journal:  Ann Lab Med       Date:  2013-08-08       Impact factor: 3.464

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.